Cargando…

Health-related quality of life in lower-risk MDS patients compared with age- and sex-matched reference populations: a European LeukemiaNet study

In myelodysplastic syndromes (MDS), health-related quality of life (HRQoL) represents a relevant patient-reported outcome, which is essential in individualized therapy planning. Prospective data on HRQoL in lower-risk MDS remain rare. We assessed HRQOL by EQ-5D questionnaire at initial diagnosis in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stauder, Reinhard, Yu, Ge, Koinig, Karin A., Bagguley, Tim, Fenaux, Pierre, Symeonidis, Argiris, Sanz, Guillermo, Cermak, Jaroslav, Mittelman, Moshe, Hellström-Lindberg, Eva, Langemeijer, Saskia, Holm, Mette Skov, Mądry, Krzysztof, Malcovati, Luca, Tatic, Aurelia, Germing, Ulrich, Savic, Aleksandar, van Marrewijk, Corine, Guerci-Bresler, Agnès, Luño, Elisa, Droste, Jackie, Efficace, Fabio, Smith, Alex, Bowen, David, de Witte, Theo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5990524/ https://www.ncbi.nlm.nih.gov/pubmed/29572506 http://dx.doi.org/10.1038/s41375-018-0089-x

Ejemplares similares

Novel dynamic outcome indicators and clinical endpoints in myelodysplastic syndrome; the European LeukemiaNet MDS Registry and MDS-RIGHT project perspective
por: de Witte, Theo, et al.
Publicado: (2020)

Cytomorphology review of 100 newly diagnosed lower-risk MDS patients in the European LeukemiaNet MDS (EUMDS) registry reveals a high inter-observer concordance
por: de Swart, Louise, et al.
Publicado: (2017)

Impact of treatment with iron chelation therapy in patients with lower-risk myelodysplastic syndromes participating in the European MDS registry
por: Hoeks, Marlijn, et al.
Publicado: (2020)

P731: SURVIVAL IN LOWER-RISK MDS PATIENTS FROM EUMDS REGISTRY BY TWO TRANSPLANT SELECTION CRITERIA - IMPLICATIONS FOR TRANSPLANT DECISION
por: Savic, Aleksandar, et al.
Publicado: (2023)

Impact of red blood cell transfusion dose density on progression-free survival in patients with lower-risk myelodysplastic syndromes
por: de Swart, Louise, et al.
Publicado: (2020)

Determinants of low health-related quality of life in patients with myelodysplastic syndromes: EUMDS Registry study
por: Stojkov, Igor, et al.
Publicado: (2023)

Raising the standards of patient‐centered outcomes research in myelodysplastic syndromes: Clinical utility and validation of the subscales of the QUALMS from the MDS‐RIGHT project
por: Efficace, Fabio, et al.
Publicado: (2022)

Development of a core outcome set for myelodysplastic syndromes – a Delphi study from the EUMDS Registry Group
por: Rochau, Ursula, et al.
Publicado: (2020)

Core set of patient-reported outcomes for myelodysplastic syndromes: an EUMDS Delphi study involving patients and hematologists
por: Stojkov, Igor, et al.
Publicado: (2021)

Labile plasma iron levels predict survival in patients with lower-risk myelodysplastic syndromes
por: de Swart, Louise, et al.
Publicado: (2018)

Toxic iron species in lower-risk myelodysplastic syndrome patients: course of disease and effects on outcome
por: Hoeks, Marlijn, et al.
Publicado: (2020)

Diagnosis and Treatment of Chronic Myelomonocytic Leukemias in Adults: Recommendations From the European Hematology Association and the European LeukemiaNet
por: Itzykson, Raphael, et al.
Publicado: (2018)

Erythropoiesis‐stimulating agents significantly delay the onset of a regular transfusion need in nontransfused patients with lower‐risk myelodysplastic syndrome
por: Garelius, H. K. G., et al.
Publicado: (2016)

Editorial: Hybrid or mixed myelodyplastic/myeloproliferative disorders: Current trends in diagnosis and treatment
por: Symeonidis, Argiris, et al.
Publicado: (2023)

Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q)
por: Fenaux, Pierre, et al.
Publicado: (2017)

Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions
por: Valent, Peter, et al.
Publicado: (2017)

Outcomes in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: a subset analysis from the MDS-004 study
por: Giagounidis, Aristoteles, et al.
Publicado: (2014)

EHA Endorsement of the European Guidelines for Myelodysplastic Syndromes, MDS-RIGHT
por: Blum, Sabine, et al.
Publicado: (2021)

Assessing the Prognosis of Patients with Myelodysplastic Syndromes (MDS)
por: Kasprzak, Annika, et al.
Publicado: (2022)

A phase 3 randomized, placebo-controlled study assessing the efficacy and safety of epoetin-α in anemic patients with low-risk MDS
por: Fenaux, Pierre, et al.
Publicado: (2018)

Impaired formation of neutrophil extracellular traps in patients with MDS
por: Brings, Carolin, et al.
Publicado: (2022)

Proteomic Case Studies of MDS in Progression: Heterogeneity and More Heterogeneity
por: Pecankova, Klara, et al.
Publicado: (2022)

Iron overload in myelodysplastic syndromes (MDS) – diagnosis, management, and response criteria: a proposal of the Austrian MDS platform
por: Valent, P, et al.
Publicado: (2008)

The challenge of individualised risk assessment and therapy planning in elderly high-risk myelodysplastic syndromes (MDS) patients
por: Stauder, Reinhard
Publicado: (2012)

European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia
por: Hochhaus, A., et al.
Publicado: (2020)

Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with Low- or Intermediate-1-risk MDS with del(5q): a comparative analysis
por: Kuendgen, A, et al.
Publicado: (2013)

Improved benefit of continuing luspatercept therapy: sub-analysis of patients with lower-risk MDS in the MEDALIST study
por: Germing, Ulrich, et al.
Publicado: (2023)

PB1999: TOBACCO SMOKING IN MDS PATIENTS – ANALYSIS FROM THE MDS PALG REGISTRY
por: Machowicz, Rafal, et al.
Publicado: (2023)

European LeukemiaNet Response Predicts Disease Progression but Not Thrombosis in Polycythemia Vera
por: Tremblay, Douglas, et al.
Publicado: (2022)

Comparison and validation of the 2022 European LeukemiaNet guidelines in acute myeloid leukemia
por: Lachowiez, Curtis A., et al.
Publicado: (2022)

European LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemia
por: Cross, Nicholas C. P., et al.
Publicado: (2023)

Treatment of Anemia in Transfusion-Dependent and Non-Transfusion-Dependent Lower-Risk MDS: Current and Emerging Strategies
por: Germing, Ulrich, et al.
Publicado: (2019)

A European survey on the detection and management of iron overload in transfusion-dependent patients with MDS
por: Giagounidis, Aristoteles, et al.
Publicado: (2011)

Azacytidine Failure Revisited: an Appraisal Based on Real-Life Data from the MDS Registry of the Hellenic Myelodysplastic Syndrome Study Group (HMDS)
por: Kotsianidis, Ioannis, et al.
Publicado: (2019)

Apoptosis-Related Gene Expression Profiling in Hematopoietic Cell Fractions of MDS Patients
por: Langemeijer, Saskia MC, et al.
Publicado: (2016)

Outcome of 129 Pregnancies in Polycythemia Vera Patients: A Report of the European LeukemiaNET
por: Wille, Kai, et al.
Publicado: (2023)

Influence of platelet count at diagnosis and during the course of disease on prognosis in MDS patients
por: Strapatsas, Judith, et al.
Publicado: (2021)

European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia
por: Steegmann, J L, et al.
Publicado: (2016)

Validation and refinement of the 2022 European LeukemiaNet genetic risk stratification of acute myeloid leukemia
por: Rausch, Christian, et al.
Publicado: (2023)

Prognostic impact of peripheral blood WT1-mRNA expression in patients with MDS
por: Rautenberg, Christina, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_qor9md8quuu49m9i3ooljg4ovu